• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Diagnosis, Staging, and Patient Selection for Locoregional Therapy to Treat Hepatocellular Carcinoma.肝细胞癌局部区域治疗的诊断、分期及患者选择
Semin Intervent Radiol. 2020 Dec;37(5):441-447. doi: 10.1055/s-0040-1719185. Epub 2020 Dec 11.
2
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.钇-90微球放射性栓塞治疗不可切除的肝细胞癌
Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2.
3
Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies.肝细胞癌的局部区域治疗方法：最新进展与管理策略
Cancers (Basel). 2020 Jul 15;12(7):1914. doi: 10.3390/cancers12071914.
4
Update on the Diagnosis and Treatment of Hepatocellular Carcinoma.肝细胞癌的诊断与治疗进展
Gastroenterol Hepatol (N Y). 2020 Oct;16(10):506-516.
5
Goals and targets for personalized therapy for HCC.肝癌个体化治疗的目标和靶点。
Hepatol Int. 2019 Mar;13(2):125-137. doi: 10.1007/s12072-018-9919-1. Epub 2019 Jan 1.
6
Management of Hepatocellular Carcinoma: Prevention, Surveillance, Diagnosis, and Staging.肝细胞癌的管理：预防、监测、诊断与分期
Exp Clin Transplant. 2017 Mar;15(Suppl 2):31-35. doi: 10.6002/ect.TOND16.L9.
7
Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.不可切除肝细胞癌的治疗选择，重点是使用钇-90树脂微球的选择性内放射治疗（SIRT）
Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.12972. Epub 2017 Jul 30.
8
Treatment strategies for locally advanced hepatocellular carcinoma.局部晚期肝细胞癌的治疗策略
Transl Gastroenterol Hepatol. 2019 Feb 18;4:12. doi: 10.21037/tgh.2019.01.02. eCollection 2019.
9
Prospective evaluation of patients with early-/intermediate-stage hepatocellular carcinoma with disease progression following arterial locoregional therapy: candidacy for systemic treatment or clinical trials.前瞻性评估经动脉局部区域治疗后疾病进展的早期/中期肝细胞癌患者：全身治疗或临床试验的适应证。
J Vasc Interv Radiol. 2013 Aug;24(8):1189-1197.e2. doi: 10.1016/j.jvir.2012.12.025. Epub 2013 Mar 7.
10
The Timing of Liver Transplantation Following Downstaging: Wait of Not to Wait?肝移植降期治疗后的时机选择：等待还是不等待？
J Gastrointest Cancer. 2020 Dec;51(4):1152-1156. doi: 10.1007/s12029-020-00491-z.

引用本文的文献

1
Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma.肝细胞癌的免疫治疗与放射治疗联合方法
Cancers (Basel). 2024 Mar 5;16(5):1058. doi: 10.3390/cancers16051058.
2
Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma.联合放疗与免疫检查点抑制治疗晚期肝细胞癌
Front Oncol. 2023 Jul 24;13:1193762. doi: 10.3389/fonc.2023.1193762. eCollection 2023.
3
Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma.立体定向体部放射治疗（SBRT）联合免疫检查点抑制剂（ICI）用于肝细胞癌和胆管癌的治疗
Cancers (Basel). 2022 Dec 22;15(1):50. doi: 10.3390/cancers15010050.
4
Combined screening analysis of aberrantly methylated-differentially expressed genes and pathways in hepatocellular carcinoma.肝细胞癌中异常甲基化差异表达基因及通路的联合筛选分析
J Gastrointest Oncol. 2022 Feb;13(1):311-325. doi: 10.21037/jgo-21-866.
5
Cysteine-rich intestinal protein 1 enhances the progression of hepatocellular carcinoma via Ras signaling.富含半胱氨酸的肠蛋白 1 通过 Ras 信号促进肝癌的进展。
Kaohsiung J Med Sci. 2022 Jan;38(1):49-58. doi: 10.1002/kjm2.12445. Epub 2021 Sep 29.

本文引用的文献

1
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
2
The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma.LI-RADS 版本 2018 MRI 治疗反应算法：消融治疗肝细胞癌的评估。
Radiology. 2020 Feb;294(2):320-326. doi: 10.1148/radiol.2019191581. Epub 2019 Dec 17.
3
Emerging agents and regimens for hepatocellular carcinoma.新兴的肝癌治疗药物和方案。
J Hematol Oncol. 2019 Oct 26;12(1):110. doi: 10.1186/s13045-019-0794-6.
4
Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study.索拉非尼联合经动脉化疗栓塞术对比单纯索拉非尼治疗晚期肝细胞癌可提高生存率：一项基于全国人群的队列研究
Cancers (Basel). 2019 Jul 15;11(7):985. doi: 10.3390/cancers11070985.
5
Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.索拉非尼联合或不联合经动脉化疗栓塞治疗晚期肝细胞癌患者的 III 期 STAH 试验。
J Hepatol. 2019 Apr;70(4):684-691. doi: 10.1016/j.jhep.2018.11.029. Epub 2018 Dec 6.
6
Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma.比较载药微球动脉化疗栓塞联合或不联合阿帕替尼治疗巴塞罗那临床肝癌分期 C 期肝癌的疗效和安全性。
BMC Cancer. 2018 Nov 19;18(1):1131. doi: 10.1186/s12885-018-5081-3.
7
Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis.钇-90经动脉放射性栓塞术与传统经动脉化疗栓塞术治疗肝细胞癌患者的系统评价和荟萃分析
Cancer Biol Med. 2018 Aug;15(3):299-310. doi: 10.20892/j.issn.2095-3941.2017.0177.
8
Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma.经动脉化疗栓塞联合微波消融与经动脉化疗栓塞治疗BCLC B期肝细胞癌的比较
Diagn Interv Radiol. 2018 Jul;24(4):219-224. doi: 10.5152/dir.2018.17528.
9
Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma.放射段切除术：早期肝细胞癌的潜在治愈性治疗方法。
Radiology. 2018 Jun;287(3):1050-1058. doi: 10.1148/radiol.2018171768. Epub 2018 Apr 24.
10
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.欧洲肝脏研究学会临床实践指南：肝细胞癌的管理
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.

肝细胞癌局部区域治疗的诊断、分期及患者选择

Diagnosis, Staging, and Patient Selection for Locoregional Therapy to Treat Hepatocellular Carcinoma.

作者信息

Berman Zachary T, Newton Isabel

机构信息

Department of Radiology, University of California San Diego, San Diego, California.

Department of Radiology, Veterans Affairs San Diego Healthcare System, San Diego, California.

出版信息

Semin Intervent Radiol. 2020 Dec;37(5):441-447. doi: 10.1055/s-0040-1719185. Epub 2020 Dec 11.

DOI:10.1055/s-0040-1719185
PMID:33328699
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7732572/
Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality and the only cancer for which the incidence and mortality are on the rise. Sensitive and specific screening and diagnostic approaches, robust staging regimens, multidisciplinary tumor boards, and patient/family education and engagement in the shared decision-making process help to identify a patient's optimal treatment options. Locoregional therapies have been the mainstay for treating intermediate-stage disease, but they are finding special applications for early and advanced disease. This review discusses the diagnosis of HCC, current accepted staging models, and treatment of HCC, with a focus on locoregional therapies.

摘要

肝细胞癌（HCC）是癌症相关死亡的第二大主要原因，也是发病率和死亡率呈上升趋势的唯一癌症。灵敏且特异的筛查和诊断方法、完善的分期方案、多学科肿瘤专家委员会以及患者/家属教育并参与共同决策过程，有助于确定患者的最佳治疗方案。局部区域治疗一直是治疗中期疾病的主要手段，但它们在早期和晚期疾病中也有特殊应用。本文综述了HCC的诊断、目前公认的分期模型以及HCC的治疗，重点关注局部区域治疗。